| Course | NR 580 Adult-Gerontology Primary Care Capstone and Intensive |
|---|---|
| Week | 7 |
| Paper type | Complex case synthesis |
| Length | About 1,140 words, 6 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Adult-Gerontology Primary Care NP (AGPCNP) |
| Updated | October 2026 |
Free sample paper for NR 580 Week 7
Complex Case Synthesis: Heart Failure Medicines That Lower Pressure Against Falls From Orthostatic Hypotension in a 76-Year-Old, and What Was Given Up to Choose
Student Name
College of Nursing, Chamberlain University
NR 580: Adult-Gerontology Primary Care Capstone and Intensive
Instructor Name
Month Day, Year
Complex Case Synthesis: Heart Failure Medicines That Lower Pressure Against Falls From Orthostatic Hypotension in a 76-Year-Old, and What Was Given Up to Choose
The Patient in Brief
A 76-year-old with heart failure with reduced ejection fraction (35%), type 2 diabetes, stage 3b kidney disease and a standing blood pressure drop of 24 points with lightheadedness. Two falls in six weeks. Medicines for heart failure: carvedilol 12.5 mg twice daily and sacubitril with valsartan 24/26 mg twice daily, both well below target doses, and furosemide 20 mg daily. Glipizide has been stopped and insulin reduced for low sugars.
The Conflict
Requirement 1: the heart failure guideline recommends that patients with reduced ejection fraction receive four drug classes at target doses where tolerated, namely an SGLT2 inhibitor, a mineralocorticoid antagonist, a beta blocker and sacubitril with valsartan or a similar agent, because together they reduce deaths and hospital admissions (Heidenreich et al., 2022). This patient takes two of the four, at low doses.
Requirement 2: prevent falls in an older adult with orthostatic hypotension, which means not adding or raising medicines that lower standing pressure.
Each is correct alone. Raising the doses would lower the standing pressure further; leaving them low leaves mortality benefit on the table.
Why Neither Requirement Can Simply Give Way
It would be tidy to say that the falls are the only real problem and the heart failure can wait, or that the heart failure guideline settles the matter and the falls must be managed some other way. Neither is true here. This patient's ejection fraction is 35%, low enough that the medicines meaningfully reduce the risk of death and admission. The falls are recent, two in six weeks, one with an injury risk from the blood thinner the patient does not take but might need if atrial fibrillation appears. Both risks are near and real.
The Choice
The choice made with the patient and the cardiologist: do not raise carvedilol or sacubitril with valsartan; add an SGLT2 inhibitor at the two-week review, provided no further low readings have occurred; do not add a mineralocorticoid receptor antagonist now, because of the potassium of 4.8 and the kidney function.
Why this order: an SGLT2 inhibitor reduced worsening heart failure or cardiovascular death in a large trial of patients with reduced ejection fraction, and its effect on blood pressure is small compared with the other classes (McMurray et al., 2019). It also protects the kidneys. Of the medicines available, it gives the most heart failure benefit for the least pressure lowering.
What Was Given Up
The mortality and admission benefit of target-dose beta blockade and target-dose sacubitril with valsartan. The guideline's full four-class therapy. The benefit of a mineralocorticoid receptor antagonist. These are real losses, and they are written down so a later reader can see they were weighed, not missed.
What Was Taken
A plan that keeps the patient upright, with one new medicine chosen for the best balance of benefit and pressure effect. The patient's own priority, to stop falling, is served directly.
The Conversation With the Cardiologist
I called the cardiologist before the patient left the clinic. The cardiologist agreed that the doses should not be raised while the patient was falling, preferred adding the SGLT2 inhibitor before a mineralocorticoid receptor antagonist given the potassium, and asked to see the patient in two months rather than six. The cardiologist also suggested that if the standing drop improved, the carvedilol could be raised by one step before the next visit. Both plans are now in the record, so the primary care and cardiology notes say the same thing.
What the Patient Said
Asked whether a slightly higher risk from the heart over the years was acceptable in return for fewer falls now, the patient said: "I'm 76. A broken hip would finish me faster than my heart." The spouse agreed. That statement is recorded as the basis for the choice.
How the Patient Was Involved
The trade was explained to the patient and spouse in plain terms: the heart medicines protect the heart over years, raising them now would make dizziness and falls more likely, and the plan keeps them where they are for three months while a new medicine with less effect on blood pressure is added. The patient asked whether this meant the heart would get worse. I answered that it might, slightly, and that the weight and breathing checks were there to catch it early.
What Must Now Be Watched
Standing blood pressure at every visit. Weight and symptoms of fluid build-up, since the doses of heart failure medicines are below target. Kidney function and potassium after the SGLT2 inhibitor starts, and genital infections. Glucose, since the SGLT2 inhibitor lowers it slightly while the insulin has just been reduced. If the standing drop improves over three months, the beta blocker dose can be raised one step at a time.
What Could Make the Choice Wrong
The choice could be wrong in two ways. If the patient's heart failure worsens over the next three months, with weight gain, breathlessness or an admission, the low doses may be costing more than the falls they prevent. If the falls continue despite the lower doses, the orthostatic hypotension may have another cause, such as autonomic neuropathy from diabetes, and the trade would have bought nothing. Either outcome would reopen the decision with the cardiologist.
How the Choice Will Be Revisited
At three months, the standing blood pressure, the fall diary, the weight and the symptoms will be reviewed together. If the standing drop is below 15 points and there have been no falls, the carvedilol will be raised by one step. If there has been an admission for heart failure, the doses will be raised despite the falls, with physical therapy and home safety measures increased to compensate. The decision is held as a three-month trial, not as a permanent limit.
Why the Choice Comes From This Patient
A general rule, such as always titrating to target doses, would have written this plan before the patient was seen. The choice here depends on this patient's falls, standing pressure, potassium and stated priority. A patient of the same age without falls would have had the doses raised, and a patient with the same falls but an ejection fraction of 50% would have had fewer heart failure medicines to weigh. The drop on standing qualifies as orthostatic hypotension by the consensus criteria (Freeman et al., 2011), so the plan treats it as a fixed constraint and not as a reading to explain away.
References
Freeman, R., Wieling, W., Axelrod, F. B., Benditt, D. G., Benarroch, E., Biaggioni, I., Cheshire, W. P., Chelimsky, T., Cortelli, P., Gibbons, C. H., Goldstein, D. S., Hainsworth, R., Hilz, M. J., Jacob, G., Kaufmann, H., Jordan, J., Lipsitz, L. A., Levine, B. D., Low, P. A., . . . van Dijk, J. G. (2011). Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clinical Autonomic Research, 21(2), 69-72. https://doi.org/10.1007/s10286-011-0119-5
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., . . . Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18), e895-e1032. https://doi.org/10.1161/CIR.0000000000001063
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Belohlavek, J., Bohm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukat, A., Ge, J., . . . Langkilde, A.-M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995-2008. https://doi.org/10.1056/NEJMoa1911303
What the NR 580 Week 7 assignment asks for
The Week 7 synthesis gets its length from a collision rather than from coverage. Carry one patient in the smallest form that makes the conflict visible, then state the conflict outright as two requirements, each correct on its own, neither of which survives the other intact. The middle of the document is the choice: what was taken, what was given up and what now has to be watched. Most rubrics mark down a synthesis that quietly adjusts one requirement until both fit, and a choice defended from a general rule rather than from this patient. Expect to say what would show the choice was wrong.
Inside the NR 580 Week 7 example
The synthesis gives the patient in one paragraph. Requirement 1 is the heart failure guideline's four drug classes at target doses; requirement 2 is fall prevention in orthostatic hypotension. A section explains why neither can simply give way. The choice keeps the current doses and adds an SGLT2 inhibitor after the low sugars stop, citing a trial in reduced ejection fraction. What was given up and what was taken are listed. The cardiologist's agreement and the patient's words about a broken hip follow. Sections on monitoring, how the choice could be wrong, the three-month review and why the choice comes from this patient close it. Each section stays with this one patient.
NR 580 Week 7 rubric: what full points look like
The worst outcome is a synthesis that dissolves its own conflict, adjusting one requirement until both fit; instructors spot it because nothing is described as a cost, and this one lists losses plainly. Nearly as damaging is a choice defended from a general rule, which could have been written before the case was read; this choice rests on the patient's falls, potassium and words. A compensating plan with nothing to watch loses a row, so monitoring is specific. Stating what would show the choice to be wrong, and when it will be revisited, earns credit for treating the choice as provisional. Recording the patient's own words about the trade grounds the choice in this person rather than in caution.
Common NR 580 Week 7 mistakes, and how to avoid them
Weak NR 580 Week 7 syntheses make the conflict disappear, often by deciding one requirement does not really apply. Others choose by citing a guideline without reference to the patient. Many omit what was given up. Monitoring is often described as close follow-up with nothing named. Few say what would prove the choice wrong. If your patient's conflict differs, send the two requirements and the patient's details, and a synthesis can be built around the choice and its cost. State both requirements as correct, choose with this patient's details, list what was given up and name the results that would make you change course. Set a date to look again.
Get a NR 580 Week 7 example written to your instructions
Send the Week 7 assignment, the case your classroom assigned and any rubric it publishes, and a custom example is written against those and returned inside 24 to 48 hours, the first free. It arrives as a complete synthesis with the collision, the concession and the compensating watch all on the page, to set your own draft against.
More NR 580 papers and AGPCNP samples
- NR 580 Week 1: Entrustment Claim Discussion Post
- NR 580 Week 2: Capstone Case Presentation
- NR 580 Week 3: Comprehensive Case Write-Up
- NR 580 Week 4: Clinical Decision Brief
- NR 580 Week 5: Capstone Gap Analysis
- NR 580 Week 6: Capstone Self-Assessment Plan
- NR 580 Week 8: Readiness Reflection
- NR 568 Week 7: Polypharmacy Case Study
- NR 579 Week 7: Ethical Dilemma Write-Up
- NR 576 Week 7: Atypical Presentation Write-Up
- NR 578 Week 7: Complex Geriatric Case Analysis
NR 580 Week 7 questions, answered
Does the conflict have to be resolved by the end?
It has to be decided, which is not the same thing. A synthesis choosing a side, naming the cost and building a watch around it has done the work. One that discovers a clever way for both requirements to be satisfied has usually softened one of them, and a marker who reads the case will notice which. Say what you accepted rather than arguing that nothing was accepted.
Can I use a case where I chose badly?
Often those read strongest. The assignment marks the reasoning available at the time and the honesty of the accounting, not the ending. What matters is that the choice is defended from what was known then, that the compensating watch is described as it actually was, and that the writer says plainly which signal would have moved them and whether the arrangement would have picked it up.
How much detail belongs on the therapy itself?
Only as much as the collision requires. This week is not marking the choice of agent or regimen for its own sake; it is marking whether that choice sits properly with the assessment above it and the follow-up beneath it. Enough specificity that a reader can see the conflict is genuine, and no more, keeps the document on the ground it is graded on.
Where can I find a free NR 580 Week 7 sample paper?
The full complex case synthesis on heart failure medicines versus falls in the 76-year-old is published on this page.
What was given up in the NR 580 Week 7 synthesis?
The benefit of target-dose beta blocker and sacubitril with valsartan, the full four-class heart failure therapy and a mineralocorticoid receptor antagonist, for now.